Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics

Theravance Biopharma, Inc. - Ordinary Shares (TBPH): $8.76

0.42 (+5.04%)

POWR Rating

Component Grades













Add TBPH to Watchlist
Sign Up

Industry: Biotech


of 450

in industry


  • Growth is the dimension where TBPH ranks best; there it ranks ahead of 81.49% of US stocks.
  • TBPH's strongest trending metric is Growth; it's been moving up over the last 169 days.
  • TBPH ranks lowest in Momentum; there it ranks in the 9th percentile.

TBPH Stock Summary

  • Theravance Biopharma Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.02% of US listed stocks.
  • TBPH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.39% of US stocks.
  • The volatility of Theravance Biopharma Inc's share price is greater than that of 93.92% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Theravance Biopharma Inc are NKTR, AVIR, EDIT, XBIT, and ADVM.
  • TBPH's SEC filings can be seen here. And to visit Theravance Biopharma Inc's official web site, go to

TBPH Valuation Summary

  • TBPH's price/sales ratio is 9.5; this is 150% higher than that of the median Healthcare stock.
  • Over the past 89 months, TBPH's price/sales ratio has gone down 3267.9.
  • TBPH's EV/EBIT ratio has moved down 0 over the prior 89 months.

Below are key valuation metrics over time for TBPH.

Stock Date P/S P/B P/E EV/EBIT
TBPH 2021-08-31 9.5 -2.0 -2.3 -4.7
TBPH 2021-08-30 9.6 -2.1 -2.3 -4.8
TBPH 2021-08-27 9.4 -2.0 -2.3 -4.7
TBPH 2021-08-26 9.4 -2.0 -2.3 -4.7
TBPH 2021-08-25 10.0 -2.1 -2.4 -4.9
TBPH 2021-08-24 10.6 -2.3 -2.6 -5.0

TBPH Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -22.61%.
  • The 2 year revenue growth rate now stands at 326.51%.
  • The 4 year net income to common stockholders growth rate now stands at -35.75%.
TBPH's revenue has moved up $18,960,000 over the prior 67 months.

The table below shows TBPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 59.095 -230.349 -225.826
2021-06-30 64.158 -261.934 -264.161
2021-03-31 66.252 -265.167 -274.643
2020-12-31 71.857 -250.403 -278.017
2020-09-30 82.626 -249.83 -285.189
2020-06-30 76.796 -217.421 -269.977

TBPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TBPH has a Quality Grade of D, ranking ahead of 23.9% of graded US stocks.
  • TBPH's asset turnover comes in at 0.144 -- ranking 228th of 682 Pharmaceutical Products stocks.
  • AVTX, SUPN, and PTCT are the stocks whose asset turnover ratios are most correlated with TBPH.

The table below shows TBPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.144 1 -0.253
2021-03-31 0.138 1 -0.250
2020-12-31 0.134 1 -0.257
2020-09-30 0.158 1 -0.273
2020-06-30 0.152 1 -0.285
2020-03-31 0.180 1 -0.288

TBPH Price Target

For more insight on analysts targets of TBPH, see our TBPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.38 Average Broker Recommendation 1.94 (Hold)

TBPH Stock Price Chart Interactive Chart >

Price chart for TBPH

TBPH Price/Volume Stats

Current price $8.76 52-week high $22.74
Prev. close $8.34 52-week low $6.10
Day low $8.19 Volume 825,592
Day high $8.77 Avg. volume 2,179,142
50-day MA $9.72 Dividend yield N/A
200-day MA $12.20 Market Cap 645.59M

Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio

Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.

TBPH Latest News Stream

Event/Time News Detail
Loading, please wait...

TBPH Latest Social Stream

Loading social stream, please wait...

View Full TBPH Social Stream

Latest TBPH News From Around the Web

Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.

Theravance Biopharma (TBPH) Investor Prsentation - Slideshow

No summary available.

Seeking Alpha | January 15, 2022

After layoffs, Peninsula biotech company looks to sublease offices, labs

The company cut three-quarters of its workforce late last year after the clinical trial failures of two drugs.

Yahoo | January 14, 2022

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced enrollment of the first patient in a Phase 4 study of YUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Success in this study is intended to capture more of YUPELRI's addressable market and further strengthen its competitive advantage.

Yahoo | January 10, 2022

Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows:

Yahoo | January 5, 2022

New-year job cuts coming to Genentech as part of Roche product development shift

Although biotech is largely booming and Bay Area life sciences companies are generally finding it tough to fill open positions, different circumstances are causing some companies to lay off employees.

Yahoo | December 22, 2021

Read More 'TBPH' Stories Here

TBPH Price Returns

1-mo -17.98%
3-mo 12.74%
6-mo -32.51%
1-year -52.16%
3-year -64.96%
5-year -69.86%
YTD -20.72%
2021 -37.82%
2020 -31.36%
2019 1.17%
2018 -8.25%
2017 -12.52%

Continue Researching TBPH

Here are a few links from around the web to help you further your research on Theravance Biopharma Inc's stock as an investment opportunity:

Theravance Biopharma Inc (TBPH) Stock Price | Nasdaq
Theravance Biopharma Inc (TBPH) Stock Quote, History and News - Yahoo Finance
Theravance Biopharma Inc (TBPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8218 seconds.